IMVT (STOCKS)
Immunovant, Inc. Common Stock
$33.360000
-0.260000 (-0.77%)
Prev close: $33.620000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Eric Venker
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,849.11M
- Employees
- 362
- P/E (TTM)
- -12.14
- P/B (TTM)
- 8.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
9
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q4)
|
$-0.73 | $-0.61 | -0.1171 | -19.11% |
|
Dec 2025 (Q3)
|
$-0.61 | $-0.73 | +0.1185 | +16.27% |
|
Sep 2025 (Q2)
|
$-0.73 | $-0.73 | +0.0015 | +0.21% |
|
Jun 2025 (Q1)
|
$-0.71 | $-0.66 | -0.0526 | -8.00% |
Financial Statements
| Operating Expenses | $532.90M |
| Income/Loss From Continuing Operations After Tax | -$505.61M |
| Income/Loss From Continuing Operations Before Tax | -$505.39M |
| Income Tax Expense/Benefit | $215.00K |
| Income Tax Expense/Benefit, Current | $215.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$505.61M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$505.61M |
| Net Income/Loss Available To Common Stockholders, Basic | -$505.61M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.77 |
| Diluted Earnings Per Share | -$2.77 |
| Basic Average Shares | 182,421,233 |
| Diluted Average Shares | 182,421,233 |
| Assets | $957.01M |
| Current Assets | $948.82M |
| Prepaid Expenses | $42.76M |
| Other Current Assets | $906.06M |
| Noncurrent Assets | $8.20M |
| Fixed Assets | $443.00K |
| Other Non-current Assets | $7.75M |
| Liabilities | $104.42M |
| Current Liabilities | $104.42M |
| Accounts Payable | $7.54M |
| Other Current Liabilities | $96.88M |
| Noncurrent Liabilities | $0.00 |
| Equity | $852.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $852.59M |
| Liabilities And Equity | $957.01M |
| Net Cash Flow From Operating Activities | -$407.31M |
| Net Cash Flow From Operating Activities, Continuing | -$407.31M |
| Net Cash Flow From Investing Activities | -$8.00K |
| Net Cash Flow From Investing Activities, Continuing | -$8.00K |
| Net Cash Flow From Financing Activities | $595.76M |
| Net Cash Flow From Financing Activities, Continuing | $595.76M |
| Exchange Gains/Losses | -$299.00K |
| Net Cash Flow | $188.14M |
| Net Cash Flow, Continuing | $188.44M |
| Comprehensive Income/Loss | -$506.34M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$506.34M |
| Other Comprehensive Income/Loss | -$506.34M |
| Other Comprehensive Income/Loss Attributable To Parent | -$729.00K |